The new FDA commissioner and Center for Biologics Evaluation and Research (CBER) director laid out their vision for the ...

The FDA plans to “rapidly make available” rare disease drugs and make use of surrogate endpoints to get promising medicines ...

If there’s anything that Dr. Vinay Prasad, the controversial new appointee to lead the Center for Biologics Evaluation and Research, or CBER, a top office at the Food and Drug Administration ...

(PRNewsFoto/National Organization for Rare Disorders (NORD)) Vinay Prasad, MD ... Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), will deliver the keynote ...

Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would look for ways ...

The controversial appointment of oncologist Vinay Prasad — an outspoken ... Now, as the director of the Center for Biologics Evaluation and Research, which oversees vaccines, gene therapies ...

T he US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines and ...

D.C. Vinay Prasad, MD, MPH, the newly appointed Director of the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), will deliver the keynote address.

Leaders from the world of cell and gene therapy shared their personal stories and policy recommendations in an extraordinary ...

and critic of pharmaceutical industry practices—as the new head of its Center for Biologics Evaluation and Research, the division responsible for regulating vaccines, gene therapies, and the ...

HHS Secretary Robert F. Kennedy Jr. said that the FDA would look for ways to fast-track approval for rare disease treatments ...